Obstructive sleep apnea is very common and is associated with a variety of serious health issues, such as cardiovascular disease and diabetes. Getting a proper diagnosis is hampered by the need for patients to visit a sleep clinic and undergo polysomnography.
This gold-standard test is complicated and requires specialized staff to interpret the results. To address these issues, a company called Sunrise has developed an at-home sleep apnea test that relies on a small wearable device. The device consists of a small sensor that a user can attach to their chin when they are about to go to sleep.
The sensor records movements of the jaw, which correlates with sleep events using artificial intelligence. Sunrise has recently launched the device in the UK, and it is relatively inexpensive, starting at £49 ($66). Medgadget had the opportunity to talk to Laurent Martinot, CEO & Co-founder of Sunrise, about the technology.
Due to its prevalence and its link with obesity and chronic cardio-metabolic diseases, Obstructive Sleep Apnoea (OSA) is a real public health problem. OSA is primarily responsible for symptoms such as daytime sleepiness (caused by sleep fragmentation), fatigue, irritability, and snoring, possibly accompanied by a feeling of suffocation or suffocation during sleep.
Non-restful sleep is accompanied by difficulty concentrating, nocturia (waking up to urinate more than once per night), libido disturbances, and disturbances in vigilance. OSA can also be responsible for disrupting the quality of life of spouses/bed neighbors of the sufferer. OSA is thus at the origin of a significant deterioration in the quality of life which can also be the origin of accidents at work and on the road. OSA is also associated with long-term consequences: cardiovascular morbidity and mortality (arterial hypertension, heart failure, atrial fibrillation, etc.), and metabolic (diabetes, obesity), and cognitive effects. It is described as an independent predictor of mortality.
Also Read: GloPRO® LIP MicroTip™ Attachment Head
